AstraZeneca: shares boosted by study results
(CercleFinance.com) - On Friday AstraZeneca shares were boosted by the announcement of positive results from a clinical trial of its treatment for paroxysmal nocturnal haemoglobinuria, a rare acquired disease.
The stock rose 1.9% after the announcement, at one point the second biggest winner on a lackluster FTSE index that was down 0.4%.
A phase III study of Danicopan met its primary endpoint as an adjunct to a C5 inhibitor (Eculizumab or Ravulizumab) in patients with paroxysmal nocturnal haemoglobinuria and clinically evident extravascular haemolysis.
This condition is characterised by sudden, often nocturnal, attacks of red cell destruction that can lead to anaemia.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The stock rose 1.9% after the announcement, at one point the second biggest winner on a lackluster FTSE index that was down 0.4%.
A phase III study of Danicopan met its primary endpoint as an adjunct to a C5 inhibitor (Eculizumab or Ravulizumab) in patients with paroxysmal nocturnal haemoglobinuria and clinically evident extravascular haemolysis.
This condition is characterised by sudden, often nocturnal, attacks of red cell destruction that can lead to anaemia.
Copyright (c) 2022 CercleFinance.com. All rights reserved.